Results 101 to 110 of about 5,866 (194)

A Recipe for State Dependent Distributed Delay Differential Equations

, 2018
We use the McKendrick equation with variable ageing rate and randomly distributed maturation time to derive a state dependent distributed delay differential equation.
Cassidy, Tyler, Craig, Morgan, Humphries, Antony R.   +2 more
core   +1 more source

Febrile Neutropenia pada Pasien Pascakemoterapi [PDF]

, 2017
Febrile neutropenia (FN) is one of the side effects caused by chemotherapy due to hematopoetic suppression that cause neutropenia and other triggerring factors such as infection.
BUDIANA, I. N. (I), FEBIANI, M. (MELINDA)   +1 more
core  

Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies—bendamustine and G-CSF support [PDF]

, 2019
Catalano, Lucio, Cerchione, Claudio, De Renzo, Amalia, Di Perna, Maria, Nappi, Davide, Pane, Fabrizio, Pepa, Roberta Della, Picardi, Marco, Pugliese, Novella   +8 more
core   +1 more source

Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. [PDF]

, 2019
BackgroundPALOMA-2 confirmed that first-line palbociclib + letrozole improved progression-free survival (hazard ratio, 0.58; 95% confidence interval, 0.46-0.72) in postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor ...
Diéras, Véronique, Ettl, Johannes, Finn, Richard S, Gauthier, Eric, Gelmon, Karen, Harbeck, Nadia, Joy, Anil Abraham, Lu, Dongrui R, Mori, Ave, Rugo, Hope S, Schnell, Patrick, Verma, Sunil   +11 more
core  

Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study [PDF]

, 2018
Background: Chemotherapy-induced neutropenia (CIN) places patients at risk of life-threatening infections. While reduction of chemotherapy dose or delay of the subsequent treatment cycle and, consequently, reduction of relative dose intensity (RDI) may ...
Bosly, André, Constenla, Manuel, Jackisch, Christian, Leonard, Robert, Paridaens, Robert, Pettengell, Ruth, Schwenkglenks, Matthias, Szucs, Thomas   +7 more
core  

Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients

Biologics: Targets & Therapy, 2016
Roberto Guariglia,1 Maria Carmen Martorelli,1 Rosa Lerose,2 Donatella Telesca,2 Maria Rita Milella,2 Pellegrino Musto3 1Unit of Hematology and Stem Cell Transplantation, 2Pharmacy Service, 3Scientific Direction, IRCCS, Referral Cancer Center of ...
Guariglia R, Martorelli MC, Lerose R, Telesca D, Milella MR, Musto P   +5 more
doaj  

Effectiveness and safety of pegylated filgrastim (Pelgraz®) for the prevention of febrile neutropenia during cancer chemotherapy in all-day practice in Germany. [PDF]

Support Care Cancer
Steinmetz T, Jungberg P, Guth D, Knoblich J, Fietz T, Göhler T, Reiser M, Totzke U, Bernhardt K.   +8 more
europepmc   +1 more source

Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone [PDF]

, 2016
Catalano, Lucio, Cerchione, Claudio, Di Perna, Maria, Migliaccio, Ilaria, Nappi, Davide, Pane, Fabrizio, Peluso, Ilaria, Picardi, Marco, Salvatore, Dalila   +8 more
core   +1 more source

The safety and effectiveness of pegfilgrastim to reduce cancer chemotherapy-induced febrile neutropenia in real-world practice in Japan: a post-marketing surveillance study. [PDF]

Support Care Cancer
Shibata N, Kuwazawa H, Yasukawa T, Iwabuchi M, Saji S.   +4 more
europepmc   +1 more source

Long-term follow-up of S0221, comparing alternative dose-schedules of anthracycline and taxane therapy in early breast cancer. [PDF]

JNCI Cancer Spectr
Ali A, Barlow WE, Moore HCF, Hobday TJ, Isaacs C, Salim M, Albain KS, Chew HK, Burton GV, Srkalovic G, McGregor BA, Flaherty LE, Lew DL, Gralow JR, Hortobagyi GN, Sharma P, Pusztai L, Budd GT.   +17 more
europepmc   +1 more source